Literature DB >> 33402695

Irritable bowel syndrome and Parkinson's disease risk: register-based studies.

Bojing Liu1, Arvid Sjölander2, Nancy L Pedersen2,3, Jonas F Ludvigsson2,4,5,6, Honglei Chen7, Fang Fang8, Karin Wirdefeldt2,9.   

Abstract

To examine whether irritable bowel syndrome (IBS) was related to the future risk of Parkinson's disease (PD), we conducted a nested case-control study in the Swedish total population including 56,564 PD cases identified from the Swedish Patient Register and 30 controls per case individually matched by sex and year of birth. Odds ratios (ORs) with 95% confidence intervals (CIs) for having a prior diagnosis of IBS were estimated using conditional logistic regression. We furthermore conducted a cohort study using the Swedish Twin Registry following 3046 IBS patients identified by self-reported abdominal symptoms and 41,179 non-IBS individuals. Through Cox proportional hazard models, we estimated hazard ratios (HRs) and 95% CIs for PD risk. In the nested case-control study, 253 (0.4%) PD cases and 5204 (0.3%) controls had a previous IBS diagnosis. IBS diagnosis was associated with a 44% higher risk of PD (OR = 1.44, 95% CI 1.27-1.63). Temporal relationship analyses showed 53% and 38% increased risk of PD more than 5 and 10 years after IBS diagnosis, respectively. In the cohort analysis based on the Swedish Twin Registry, there was no statistically significantly increased risk of PD related to IBS (HR = 1.25, 95% CI = 0.87-1.81). Our results suggest a higher risk of PD diagnosis after IBS. These results provide additional evidence supporting the importance of the gut-brain axis in PD.

Entities:  

Year:  2021        PMID: 33402695      PMCID: PMC7785733          DOI: 10.1038/s41531-020-00145-8

Source DB:  PubMed          Journal:  NPJ Parkinsons Dis        ISSN: 2373-8057


  46 in total

Review 1.  Pathophysiology of irritable bowel syndrome.

Authors:  Gerald J Holtmann; Alexander C Ford; Nicholas J Talley
Journal:  Lancet Gastroenterol Hepatol       Date:  2016-09-08

2.  A new method of classifying prognostic comorbidity in longitudinal studies: development and validation.

Authors:  M E Charlson; P Pompei; K L Ales; C R MacKenzie
Journal:  J Chronic Dis       Date:  1987

Review 3.  Irritable bowel syndrome: a clinical review.

Authors:  William D Chey; Jacob Kurlander; Shanti Eswaran
Journal:  JAMA       Date:  2015-03-03       Impact factor: 56.272

Review 4.  Parkinson's disease: mechanisms and models.

Authors:  William Dauer; Serge Przedborski
Journal:  Neuron       Date:  2003-09-11       Impact factor: 17.173

Review 5.  Stages in the development of Parkinson's disease-related pathology.

Authors:  Heiko Braak; Estifanos Ghebremedhin; Udo Rüb; Hansjürgen Bratzke; Kelly Del Tredici
Journal:  Cell Tissue Res       Date:  2004-08-24       Impact factor: 5.249

6.  Autoimmune disease and risk for Parkinson disease: a population-based case-control study.

Authors:  K Rugbjerg; S Friis; B Ritz; E S Schernhammer; L Korbo; J H Olsen
Journal:  Neurology       Date:  2009-09-23       Impact factor: 9.910

7.  More than constipation - bowel symptoms in Parkinson's disease and their connection to gut microbiota.

Authors:  T H Mertsalmi; V T E Aho; P A B Pereira; L Paulin; E Pekkonen; P Auvinen; F Scheperjans
Journal:  Eur J Neurol       Date:  2017-09-11       Impact factor: 6.089

8.  External review and validation of the Swedish national inpatient register.

Authors:  Jonas F Ludvigsson; Eva Andersson; Anders Ekbom; Maria Feychting; Jeong-Lim Kim; Christina Reuterwall; Mona Heurgren; Petra Otterblad Olausson
Journal:  BMC Public Health       Date:  2011-06-09       Impact factor: 3.295

9.  The Prevalence of Constipation and Irritable Bowel Syndrome in Parkinson's Disease Patients According to Rome III Diagnostic Criteria.

Authors:  Takayasu Mishima; Jiro Fukae; Shinsuke Fujioka; Kotoe Inoue; Yoshio Tsuboi
Journal:  J Parkinsons Dis       Date:  2017       Impact factor: 5.568

10.  Intestinal Dysbiosis and Lowered Serum Lipopolysaccharide-Binding Protein in Parkinson's Disease.

Authors:  Satoru Hasegawa; Sae Goto; Hirokazu Tsuji; Tatsuya Okuno; Takashi Asahara; Koji Nomoto; Akihide Shibata; Yoshiro Fujisawa; Tomomi Minato; Akira Okamoto; Kinji Ohno; Masaaki Hirayama
Journal:  PLoS One       Date:  2015-11-05       Impact factor: 3.240

View more
  5 in total

Review 1.  The microbiome-gut-brain axis in Parkinson disease - from basic research to the clinic.

Authors:  Ai Huey Tan; Shen Yang Lim; Anthony E Lang
Journal:  Nat Rev Neurol       Date:  2022-06-24       Impact factor: 44.711

Review 2.  Epidemiological Evidence for an Immune Component of Parkinson's Disease.

Authors:  Paulina Gonzalez-Latapi; Connie Marras
Journal:  J Parkinsons Dis       Date:  2022       Impact factor: 5.520

3.  Investigating the efficacy and safety of elobixibat, an ileal bile acid transporter inhibitor, in patients with Parkinson's disease with chronic constipation: a multicentre, placebo-controlled, randomised, double-blind, parallel-group stud (CONST-PD).

Authors:  Taku Hatano; Genko Oyama; Yasushi Shimo; Kotaro Ogaki; Noriko Nishikawa; Jiro Fukae; Ryota Nakamura; Naohide Kurita; Taiji Tsunemi; Yutaka Oji; Shinji Saiki; Kenya Nishioka; Haruka Takeshige-Amano; Daisuke Taniguchi; Takashi Ogawa; Hikaru Kamo; Hiroto Eguchi; Atsuhito Fuse; Asuka Nakajima; Masayoshi Kano; Sho Nakajima; Naotake Yanagisawa; Nobutaka Hattori
Journal:  BMJ Open       Date:  2022-02-11       Impact factor: 3.006

Review 4.  Mechanistic Insights Into Gut Microbiome Dysbiosis-Mediated Neuroimmune Dysregulation and Protein Misfolding and Clearance in the Pathogenesis of Chronic Neurodegenerative Disorders.

Authors:  Piyush Padhi; Carter Worth; Gary Zenitsky; Huajun Jin; Kumar Sambamurti; Vellareddy Anantharam; Arthi Kanthasamy; Anumantha G Kanthasamy
Journal:  Front Neurosci       Date:  2022-02-25       Impact factor: 4.677

Review 5.  The relationship between Parkinson's disease and gastrointestinal diseases.

Authors:  Jiaqi Zeng; Xinchan Wang; Fei Pan; Zhiqi Mao
Journal:  Front Aging Neurosci       Date:  2022-08-10       Impact factor: 5.702

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.